Search

Your search keyword '"Kuzuya, K."' showing total 182 results
Start Over Author "Kuzuya, K."
182 results on '"Kuzuya, K."'

5. THU0734-HPR Novel experience equipment for rheumatoid hand-fingers

Author

Kusumoto, M., primary, Tsuji, S., additional, Toshiharu, M., additional, Kushimoto, Y., additional, Ise, N., additional, Yoshida, N., additional, Kawai, S., additional, Kyrosawa, T., additional, Oguro, E., additional, Okita, Y., additional, Kuzuya, K., additional, Matsuoka, H., additional, Teshigawara, S., additional, Yoshimura, M., additional, Harada, Y., additional, Noguchi, T., additional, Matsushita, M., additional, Hagio, K., additional, Akita, S., additional, Ohshima, S., additional, Hashimoto, J., additional, and Saeki, Y., additional

Published
2018
Full Text
View/download PDF

7. AB0282 Predicting The Responses To Biological Therapy by Two Kinds of Antibodies Titers against Porphyromonas Gingivalis in RA Patients

Author

Matsushita, M., primary, Okada, M., additional, Kobayashi, T., additional, Yoshie, H., additional, Kuzuya, K., additional, Matsuoka, H., additional, Shimizu, T., additional, Nii, T., additional, Teshigawara, S., additional, Tanaka, E., additional, Tsuji, S., additional, Ohshima, S., additional, Hashimoto, J., additional, and Saeki, Y., additional

Published
2016
Full Text
View/download PDF

8. Lack of association between a disease-susceptible single-nucleotide polymorphism, rs2230926 of , and tumour necrosis factor inhibitor therapeutic failure in Japanese patients with rheumatoid arthritis.

Author

Matsuoka, H, Kabata, D, Taura, A, Matsui, T, Takahi, K, Hirano, F, Katayama, M, Okamoto, A, Suenaga, Y, Suematsu, E, Yoshizawa, S, Ohmura, K, Ito, S, Takaoka, H, Oguro, E, Kuzuya, K, Okita, Y, Udagawa, C, Yoshimura, M, and Teshigawara, S

Subjects
SINGLE nucleotide polymorphisms, GOLIMUMAB, NECROSIS, CANCER, NF-kappa B, ARYL hydrocarbon receptors
Abstract

Biological disease-modifying anti-rheumatic drugs (bDMARDs) against pathogenic proinflammatory cytokines and lymphocytes, such as tumour necrosis factor- (TNF- ), interleukin-6, T cells and B cells, have been developed and have become leading drugs in the treatment of rheumatoid arthritis (RA). Here, we focused on I TNFAIP3 i as a possible genetic marker for TNFi therapeutic response and examined the association of one of the representative disease-susceptible SNPs of I TNFAIP3 i , rs2230926, with therapeutic failure of TNFi. [Extracted from the article]

Published
2020
Full Text
View/download PDF

10. Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) Protocol 0102.

Author

Katsumata, N., primary, Yoshikawa, H., additional, Kobayashi, H., additional, Saito, T., additional, Kuzuya, K., additional, Mizunoe, T., additional, Hiura, M., additional, Kasamatsu, T., additional, Shibata, T., additional, and Kamura, T., additional

Published
2010
Full Text
View/download PDF

11. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study

Author

Takano, M., primary, Sugiyama, T., additional, Yaegashi, N., additional, Sakuma, M., additional, Suzuki, M., additional, Saga, Y., additional, Kuzuya, K., additional, Kigawa, J., additional, Shimada, M., additional, Tsuda, H., additional, Moriya, T., additional, Yoshizaki, A., additional, Kita, T., additional, and Kikuchi, Y., additional

Published
2008
Full Text
View/download PDF

20. Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study

Author

Gynecologic Oncology Group (Tokai G, Tokai, primary, Kuzuya, K., additional, Ishikawa, H., additional, Kikkawa, F., additional, Nawa, A., additional, Fujimura, H., additional, Iwase, A., additional, Arii, Y., additional, Kawai, M., additional, Hattori, S., additional, Sakakibara, K., additional, Sasayama, E., additional, Furuhashi, Y., additional, Suzuki, T., additional, Mizutani, S., additional, and Nakanishi, T., additional

Published
2001
Full Text
View/download PDF

30. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).

Author

Katsumata, N, Yoshikawa, H, Kobayashi, H, Saito, T, Kuzuya, K, Nakanishi, T, Yasugi, T, Yaegashi, N, Yokota, H, Kodama, S, Mizunoe, T, Hiura, M, Kasamatsu, T, Shibata, T, and Kamura, T

Subjects
RANDOMIZED controlled trials, ADJUVANT treatment of cancer, CANCER chemotherapy, CERVICAL cancer treatment, ONCOLOGIC surgery, ONCOLOGY, MEDICINE, SQUAMOUS cell carcinoma
Abstract

Background:A phase III trial was conducted to determine whether neoadjuvant chemotherapy (NACT) before radical surgery (RS) improves overall survival.Methods:Patients with stage IB2, IIA2, or IIB squamous cell carcinoma of the uterine cervix were randomly assigned to receive either BOMP (bleomycin 7 mg days 1-5, vincristine 0.7 mg m−2 day 5, mitomycin 7 mg m−2 day 5, cisplatin 14 mg m−2 days 1-5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group) or RS alone (RS group). Patients with pathological high-risk factors received postoperative radiotherapy (RT). The primary end point was overall survival.Results:A total of 134 patients were randomly assigned to treatment. This study was prematurely terminated at the first planned interim analysis because overall survival in the NACT group was inferior to that in the RS group. Patients who received postoperative RT were significantly lower in the NACT group (58%) than in the RS group (80%; P=0.015). The 5-year overall survival was 70.0% in the NACT group and 74.4% in the RS group (P=0.85).Conclusion:Neoadjuvant chemotherapy with BOMP regimen before RS did not improve overall survival, but reduced the number of patients who received postoperative RT. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

32. Immunotherapy using the streptococcal preparation OK‐432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group

Author

Noda, K, primary, Teshima, K, additional, Tekeuti, K, additional, Hasegawa, K, additional, Inoue, K‐Y, additional, Yamashita, K, additional, Sawaragi, I, additional, Nakajima, T, additional, Takashima, E, additional, Ikeuchi, M, additional, Sekiba, K, additional, Okuda, H, additional, Ichijo, M, additional, Saito, T, additional, Ozawa, M, additional, Tamura, H, additional, Chihara, T, additional, Kuzuya, K, additional, and Ozaki, M, additional

Published
1990
Full Text
View/download PDF

39. Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study

Author

GOG), Tokai Gynecologic Oncology Group (Tokai, Kuzuya, K., Ishikawa, H., Nakanishi, T., Kikkawa, F., Nawa, A., Fujimura, H., Iwase, A., Arii, Y., Kawai, M., Hattori, S., Sakakibara, K., Sasayama, E., Furuhashi, Y., Suzuki, T., and Mizutani, S.

Abstract

Abstract: Background. A multicenter, phase I study of combination therapy with paclitaxel and carboplatin for epithelial ovarian cancer was conducted to determine the safety and recommended dosages for Japanese women. Methods. Paclitaxel was administered intravenously over a 3-h period, followed by carboplatin administered intravenously over a 1.5-h period. A modified continual reassessment method (mCRM) was used in two treatment arms to establish the maximum tolerated dose (MTD) and recommended doses of the combination. In group A, the dose of paclitaxel (175 mg/m2) was constant and the dose of carboplatin was increased from 4 to 7 in terms of the target area under the plasma concentration-versus-time curve (AUC). In group B, the dose of carboplatin was constant (AUC 6) and paclitaxel was administered at two dose levels (160 and 175 mg/m2). In both groups, the carboplatin dose was limited to a maximum of 800 mg/body for each administration. Results. Because the calculated probability of toxicity was greatest at a dose of paclitaxel 175 mg/m2 and carboplatin AUC 7, this dose was designated the MTD in group A. Based on this result, treatment in group B was initiated at doses of paclitaxel of 160 mg/m2 and carboplatin AUC 6. While the dose of paclitaxel was escalated to 175 mg/m2, the safety of the combination was confirmed. The most frequent adverse effect was neutropenia, which resolved promptly with the appropriate use of granulocyte-colony stimulating factor (G-CSF). No other severe hematologic or nonhematologic toxicities were observed. Conclusions. Our study demonstrated that the recommended dose for this combination regimen should be paclitaxel 175 mg/m2 plus carboplatin AUC 6 (maximum dose, 800 mg/body).

Published
2001
Full Text
View/download PDF

42. Association of human leukocyte antigen-B1*03 with cervical cancer in Japanese women aged 35 years and younger

Author

Nawa, A., Nishiyama, Y., Kobayashi, T., Wakahara, Y., Okamoto, T., Kikkawa, F., Suganuma, N., Goto, S., Kuzuya, K., and Tomoda, Y.

Subjects
Cervical cancer -- Genetic aspects, Women -- Japan, Leukocytes -- Physiological aspects, Business, Health care industry
Abstract

According to the authors' abstract of an article published in Cancer, 'BACKGROUND: An association of human leukocyte antigen (HLA)-DQw3 alleles with squamous cell carcinoma (SCC) of the cervix has been [...]

Published
1995

43. Kanzo

Author

Kuzuya, K., primary, Hosoda, S., additional, Ogasawara, K., additional, Irino, J., additional, and Nonomura, Y., additional

Published
1962
Full Text
View/download PDF

44. Kanzo

Author

Takino, T., primary, Takamori, S., additional, Sakanaka, T., additional, Hasegawa, H., additional, Ogawa, D., additional, Toyoda, E., additional, Tabuchi, K., additional, Kuzuya, K., additional, and Masuda, M., additional

Published
1972
Full Text
View/download PDF

45. Kanzo

Author

Ichida, F, primary, Shiraishi, T, additional, Kuzuya, K, additional, Ota, Y, additional, Hirayama, C, additional, and Onoda, T, additional

Published
1969
Full Text
View/download PDF

47. Lack of association between a disease-susceptible single-nucleotide polymorphism, rs2230926 of TNFAIP3 , and tumour necrosis factor inhibitor therapeutic failure in Japanese patients with rheumatoid arthritis.

Author

Matsuoka H, Kabata D, Taura A, Matsui T, Takahi K, Hirano F, Katayama M, Okamoto A, Suenaga Y, Suematsu E, Yoshizawa S, Ohmura K, Ito S, Takaoka H, Oguro E, Kuzuya K, Okita Y, Udagawa C, Yoshimura M, Teshigawara S, Harada Y, Isoda K, Yoshida Y, Ohshima S, Tohma S, and Saeki Y

Subjects
Adalimumab therapeutic use, Adult, Aged, Antibodies, Monoclonal therapeutic use, Arthritis, Rheumatoid genetics, Asian People, Etanercept therapeutic use, Female, Humans, Infliximab therapeutic use, Japan, Male, Middle Aged, Polymorphism, Single Nucleotide, Prognosis, Treatment Failure, Arthritis, Rheumatoid drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use, Tumor Necrosis Factor alpha-Induced Protein 3 genetics
Published
2020
Full Text
View/download PDF

48. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.

Author

Kuzuya K, Morita T, and Kumanogoh A

Subjects
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis mortality, Cyclophosphamide adverse effects, Humans, Immunosuppressive Agents adverse effects, Leukopenia chemically induced, Mycophenolic Acid adverse effects, Randomized Controlled Trials as Topic, Recurrence, Treatment Outcome, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy, Cyclophosphamide therapeutic use, Immunosuppressive Agents therapeutic use, Mycophenolic Acid therapeutic use, Remission Induction methods
Abstract

Objectives: A few studies on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treatments have shown the therapeutic efficacy of mycophenolate mofetil (MMF). However, the therapeutic efficacy of MMF compared with that of cyclophosphamide (CYC) in patients with AAV has not been established. We conducted a systematic review and meta-analysis to assess the efficacy of MMF as a remission induction therapy in patients with AAV comparing it with the efficacy of CYC., Methods: We searched randomised controlled trials (RCTs) comparing the efficacy of MMF with that of CYC in patients with AAV on three different websites: PubMed, Cochrane Library and Google Scholar. We compared the difference in the relative risk (RR) of each outcome based on a Mantel-Haenszel random-effects model., Results: We analysed data from four RCTs with 300 patients for the study. The 6-month remission rate (RR 1.09, 95% CI 0.86 to 1.38, p=0.48), the 6-month ANCA negativity (RR 1.31, 95% CI 0.91 to 1.90, p=0.15) and the long-term relapse rate (RR 1.36, 95% CI 0.80 to 2.31, p=0.26) were all similar between the two treatments. The rates of death, infection and leucopenia were also similar between the two groups (RR 1.05, 95% CI 0.40 to 2.74, p=0.93; RR 1.26, 95% CI 0.79 to 2.01, p=0.33; RR 0.45, 95% CI 0.16 to 1.32, p=0.15, respectively)., Conclusions: We found no difference between the therapeutic efficacy of MMF and that of CYC in patients with AAV. MMF may be an alternative remission induction therapy in patients with non-life-threatening AAV., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2020
Full Text
View/download PDF

49. Diffusion Weighted Whole Body Imaging with Background Body Signal Suppression (DWIBS) Was Useful for the Diagnosis and Follow-up of Giant Cell Arteritis.

Author

Matsuoka H, Yoshida Y, Oguro E, Murata A, Kuzuya K, Okita Y, Teshigawara S, Yoshimura M, Isoda K, Harada Y, Kaminou T, Ohshima S, and Saeki Y

Subjects
Administration, Oral, Aged, Diffusion Magnetic Resonance Imaging methods, Female, Follow-Up Studies, Humans, Multimodal Imaging methods, Positron Emission Tomography Computed Tomography methods, Treatment Outcome, Whole Body Imaging methods, Anti-Inflammatory Agents therapeutic use, Aorta, Abdominal diagnostic imaging, Aorta, Abdominal physiopathology, Giant Cell Arteritis diagnostic imaging, Giant Cell Arteritis drug therapy, Giant Cell Arteritis physiopathology, Prednisolone therapeutic use
Abstract

A 66-year-old woman with symptoms of fatigue and headache was diagnosed with giant cell arteritis (GCA). Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) revealed the strong accumulation of FDG in the descending aorta, abdominal aorta, bilateral subclavian artery, and total iliac artery. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) showed signal enhancement at the descending aorta and abdominal aorta. We repeated FDG-PET and DWIBS 2 months after the initiation of therapy with prednisolone. In line with the FDG-PET findings, the signal enhancement of the aortic wall completely vanished on DWIBS. DWIBS may be a novel useful tool for the diagnosis and follow-up of GCA treatment.

Published
2019
Full Text
View/download PDF

50. Diffusion-weighted Whole-body Imaging with Background Body Signal Suppression (DWIBS) as a Novel Imaging Modality for Disease Activity Assessment in Takayasu's Arteritis.

Author

Oguro E, Ohshima S, Kikuchi-Taura A, Murata A, Kuzuya K, Okita Y, Matsuoka H, Teshigawara S, Yoshimura M, Yoshida Y, Isoda K, Kudo-Tanaka E, Harada Y, Kaminou T, and Saeki Y

Subjects
Adult, Back Pain etiology, C-Reactive Protein metabolism, Carotid Artery, Common, Carotid Stenosis etiology, Carotid Stenosis pathology, Computed Tomography Angiography, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Magnetic Resonance Imaging methods, Multimodal Imaging, Neck Pain etiology, Recurrence, Subclavian Steal Syndrome etiology, Subclavian Steal Syndrome pathology, Takayasu Arteritis drug therapy, Ultrasonography, Whole Body Imaging methods, Anti-Inflammatory Agents administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Prednisolone administration & dosage, Takayasu Arteritis pathology
Abstract

A 26-year-old woman with Takayasu's arteritis (TAK) experienced back and neck pain during tocilizumab (TCZ) treatment. The levels of C-reactive protein were normal, and ultrasonography revealed no significant changes. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) showed signal enhancement in the walls of several arteries. Contrast computed tomography showed arterial inflammation in the same lesion. After increasing the dose of prednisolone and TCZ, all signal enhancements decreased and continued to decrease, as observed on days 76 and 132. Thus, DWIBS may be a novel imaging modality for assessing the disease activity of TAK, particularly during follow-up.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results